The study by Demirović et al. [59] investigated the expression of MAGE-A3/4 and NY-ESO-1 in RO and ChRCC, finding significant differences in the expression of these cancer testis antigens between the two tumour types, which may have diagnostic implications. This evidence concerns the gene MAGEA3 and neoplasm.